Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN1 | Q05586 | 5/20 | 0.48 |
| ▸ | GRIN2B | Q13224 | 5/20 | 0.48 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.45 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | TAOK1 | Q7L7X3 | 1/20 | 0.41 |
| ▸ | TAOK3 | Q9H2K8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4640685 | 0.92 | GRIN1 (0.48) | GRIN1GRIN2BADORA2BADORA1ALDH1A1 | |
| SCHEMBL4641751 | 0.84 | TRPV1 (0.46) | — | |
| SCHEMBL4640678 | 0.83 | TRPV1 (0.52) | — | |
| SCHEMBL4640484 | 0.81 | GRIN1 (0.47) | GRIN1GRIN2B | |
| SCHEMBL4641434 | 0.81 | TRPV1 (0.52) | — | |
| SCHEMBL5276761 | 0.80 | GRIN1 (0.59) | GRIN1GRIN2BADORA2BADORA1TAOK1 | |
| SCHEMBL5320786 | 0.79 | TRPV1 (0.52) | — | |
| SCHEMBL5279369 | 0.78 | TRPV1 (0.52) | — | |
| SCHEMBL5276305 | 0.78 | GRIN1 (0.52) | GRIN1GRIN2B | |
| SCHEMBL5321970 | 0.77 | TRPV1 (0.52) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1824837-B1 | SUBSTITUTED N-SULFONYLAMINOBENZYL-2-PHENOXY ACETAMIDE COMPOUNDS | PFIZER (US) | 2008-08-13 | — | — | EP | claimed |
| US-7214824-B2 | Substituted N-sulfonylaminobenzyl-2-phenoxyacetamide compounds as VR1 receptor agonists | PFIZER INC. (US) | 2007-05-08 | — | — | US | claimed |
| US-20060100460-A1 | Substituted N-sulfonylaminobenzyl-2-phenoxyacetamide compounds as VR1 receptor agonists | PFIZER, INC. | 2006-05-11 | — | — | US | claimed |
| EP-1824837-B1 | SUBSTITUTED N-SULFONYLAMINOBENZYL-2-PHENOXY ACETAMIDE COMPOUNDS | PFIZER (US) | 2008-08-13 | — | — | EP | disclosed |
| US-7214824-B2 | Substituted N-sulfonylaminobenzyl-2-phenoxyacetamide compounds as VR1 receptor agonists | PFIZER INC. (US) | 2007-05-08 | — | — | US | disclosed |
| US-7214824-B2 | Substituted N-sulfonylaminobenzyl-2-phenoxyacetamide compounds as VR1 receptor agonists | PFIZER INC. (US) | 2007-05-08 | — | — | US | disclosed |
| US-7214824-B2 | Substituted N-sulfonylaminobenzyl-2-phenoxyacetamide compounds as VR1 receptor agonists | PFIZER INC. (US) | 2007-05-08 | — | — | US | disclosed |
| US-20060100460-A1 | Substituted N-sulfonylaminobenzyl-2-phenoxyacetamide compounds as VR1 receptor agonists | PFIZER, INC. | 2006-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100460-A1 | Substituted N-sulfonylaminobenzyl-2-phenoxyacetamide compounds as VR1 receptor agonists | CNR1, AVPR1A, OPRL1 | GRIN1 171/4885GRIN2B 465/4885ADORA2B 278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.